Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer
Authors
Keywords
Cancer Stem Cell, Invasive breast cancer, Prognosis, CD133
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-15
DOI
10.1007/s10549-018-05085-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis
- (2018) Sasagu Kurozumi et al. BREAST CANCER RESEARCH AND TREATMENT
- Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes
- (2018) Chitra Joseph et al. BRITISH JOURNAL OF CANCER
- Breast cancer intratumour heterogeneity: current status and clinical implications
- (2018) Chitra Joseph et al. HISTOPATHOLOGY
- Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis
- (2018) Guo-Li Shao et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma
- (2017) Leili Saeednejad Zanjani et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- CD133 mediates the TGF‑β1‑induced activation of the PI3K/ERK/P70S6K signaling pathway in gastric cancer cells
- (2017) Youlong Zhu et al. Oncology Letters
- The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
- (2016) Bernard Pereira et al. Nature Communications
- CD133, Selectively Targeting the Root of Cancer
- (2016) Jörg Schmohl et al. Toxins
- Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer
- (2015) Sung Jeep Kim et al. Journal of Breast Cancer
- ActivatingPIK3CAMutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer
- (2015) Christian D. Young et al. MOLECULAR & CELLULAR PROTEOMICS
- The PI3K-PKB/Akt Pathway
- (2015) Brian A. Hemmings et al. Cold Spring Harbor Perspectives in Biology
- Characteristics of basal cytokeratin expression in breast cancer
- (2013) Alaa T. Alshareeda et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers
- (2013) Anita Bane et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer genes: beyond BRCA1 and BRCA2
- (2013) Ana Vega Frontiers in Bioscience-Landmark
- Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer
- (2013) Kousuke Hashimoto et al. Gastric Cancer
- PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line
- (2013) SEOK-HO MOON et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness
- (2013) Federica Brugnoli et al. Molecular Cancer
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma
- (2012) Olga Shakhova et al. NATURE CELL BIOLOGY
- bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer
- (2011) Pascal Jézéquel et al. BREAST CANCER RESEARCH AND TREATMENT
- Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival
- (2011) I. A. Silva et al. CANCER RESEARCH
- Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma
- (2011) Po Zhao et al. CANCER SCIENCE
- CD133 expression associated with poor prognosis in ovarian cancer
- (2011) Jing Zhang et al. MODERN PATHOLOGY
- MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
- (2010) Mohammed A. Aleskandarany et al. BREAST CANCER RESEARCH AND TREATMENT
- Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells
- (2010) Y. K. Wang et al. CARCINOGENESIS
- Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks
- (2010) Kouichi Tabu et al. Molecular Cancer
- Triple-negative breast cancer--current status and future directions
- (2009) O. Gluz et al. ANNALS OF ONCOLOGY
- PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis
- (2009) Mohammed A. Aleskandarany et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic Significance of the Cancer Stem Cell Markers CD133, CD44, and CD166 in Colorectal Cancer
- (2009) David Horst et al. CANCER INVESTIGATION
- Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
- (2009) E. A. Rakha et al. CLINICAL CANCER RESEARCH
- CD133 expression is an independent prognostic marker for low survival in colorectal cancer
- (2008) D Horst et al. BRITISH JOURNAL OF CANCER
- Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients
- (2008) F. Zeppernick et al. CLINICAL CANCER RESEARCH
- Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells
- (2008) Lilly Y. W. Bourguignon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More